Drug Trial Radar · NCT02038738
68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors
Last checked: Nov 20, 2026Latest source record: Jan 17, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
250
Planned (sponsor's estimate)
Start
Mar 2014
Primary completion
Mar 2019
Sponsor
- Lead sponsor
- Ochsner Health SystemAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 17, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Neuroendocrine cancer is an unusual disease and often goes undetected by routine imaging. The 68Ga-DOTATATE PET Scan is a novel scanning method that may have improved sensitivity and resolution specifically for neuroendocrine tumors. Patients with neuroendocrine tumors will be imaged with this agent and it will be compared to conventional imaging methods to determine the safety and efficacy of this radiopharmaceutical.
Conditions
- Neuroendocrine
- Neuroendocrine Tumor
- Neuroendocrine Cancer
- Neuroendocrine Carcinoma
- Carcinoid
- Carcinoid Tumor
- Islet Cell Tumor
- Apudoma
Interventions
68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography.Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Adverse Events as a Measure of Safety and TolerabilityTime frame: 5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ochsner Medical Center - Kenner
Kenner, Louisiana
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.